EXPD:NYSEExpeditors International of Washington, Inc. Analysis
Data as of 2026-04-01 - not real-time
$144.31
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
Expeditors International (EXPD) is trading around $144, just above its 20‑day SMA (~$143) and nestled between a support level of $138.6 and resistance at $148.5. The 14‑day RSI sits at 48, indicating neutral momentum, while the MACD histogram turned positive, providing a mild bullish signal. However, the DCF‑derived fair value of roughly $87 points to a significant overvaluation, reflected in a -3.5% downside estimate.
Fundamentally, the company remains robust. ROE exceeds 35%, operating cash flow tops $1 bn, and debt‑to‑equity is modest at about 24%, supporting financial flexibility. The dividend yield of ~1% is underpinned by a payout ratio below 30%, suggesting sustainability. Although the trailing PE (~24) is below the industry average of 29, the price‑to‑book ratio of 8.2 signals a premium market price. The “Extreme Greed” reading on the Fear & Greed Index underscores heightened market optimism that may be ahead of fundamentals.
Fundamentally, the company remains robust. ROE exceeds 35%, operating cash flow tops $1 bn, and debt‑to‑equity is modest at about 24%, supporting financial flexibility. The dividend yield of ~1% is underpinned by a payout ratio below 30%, suggesting sustainability. Although the trailing PE (~24) is below the industry average of 29, the price‑to‑book ratio of 8.2 signals a premium market price. The “Extreme Greed” reading on the Fear & Greed Index underscores heightened market optimism that may be ahead of fundamentals.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Neutral technical indicators with slight bullish MACD
- Overvaluation relative to DCF fair value
- Strong dividend sustainability
Medium Term
1–3 yearsNeutral
Model confidence: 7/10
Key Factors
- High ROE and solid cash generation
- Premium valuation but stable earnings growth
- Low debt and healthy balance sheet
Long Term
> 3 yearsNeutral
Model confidence: 7/10
Key Factors
- Consistent profitability and cash flow
- Sustainable dividend with low payout ratio
- Valuation premium may persist but fundamentals remain strong
Key Metrics & Analysis
Financial Health
Revenue Growth-3.30%
Profit Margin7.32%
P/E Ratio24.3
ROE35.43%
ROA13.64%
Debt/Equity24.20
P/B Ratio8.2
Op. Cash Flow$1.0B
Free Cash Flow$803.0M
Industry P/E29.1
Technical Analysis
TrendNeutral
RSI48.4
Support$138.59
Resistance$148.51
MA 20$143.43
MA 50$150.17
MA 200$134.37
MACDBullish
VolumeDecreasing
Fear & Greed Index77.61
Valuation
Fair Value$86.91
Target Price$139.29
Upside/Downside-3.48%
GradeOvervalued
TypeBlend
Dividend Yield1.08%
Risk Assessment
Beta0.79
Volatility34.46%
Sector RiskMedium
Reg. RiskLow
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.